绿叶制药(02186)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02186 绿叶制药

休市中 09-11 16:08:55

1.800

-0.030

-1.64%

最高1.820	最低1.790	成交量1,611万
今开1.820	昨收1.830	日振幅1.64%
总市值71.91亿	流通市值71.91亿	总股本39.95亿
成交额2,901万	换手率0.40%	流通股本39.95亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02186","market":"HK","secType":"STK","nameCN":"绿叶制药","latestPrice":1.8,"timestamp":1789114135003,"preClose":1.83,"halted":0,"volume":16109500,"delay":0,"changeRate":-0.016393442622950834,"floatShares":3995000000,"shares":3995000000,"eps":0.1857532173483315,"marketStatus":"休市中","change":-0.03,"latestTime":"09-11 16:08:55","open":1.82,"high":1.82,"low":1.79,"amount":29009690,"amplitude":0.016393,"askPrice":1.805,"askSize":1680500,"bidPrice":1.8,"bidSize":11000,"shortable":3,"etf":0,"ttmEps":0.20296097118024503,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":7,"adr":0,"listingDate":1404835200000,"exchange":"SEHK","adjPreClose":1.83,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"volumeRatio":0.7372532687766974,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02186","defaultTab":"news","newsList":[{"id":"2665467933","title":"港股异动 | 剂泰科技-P(07666)早盘涨超7% 剂泰携手绿叶制药 成为其首家AI药物递送战略合作单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2665467933","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665467933?lang=zh_cn&edition=full","pubTime":"2026-09-08 10:03","pubTimestamp":1788832998,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，剂泰科技-P早盘涨超7%。截至发稿，涨5.65%，报16.28港元，成交额7068.61万港元。消息面上，剂泰科技与绿叶制药在北京正式签署长期战略合作协议，剂泰科技成为绿叶制药在AI药物递送领域的首家战略合作单位。值得注意的是，上交所发布通知，剂泰科技-P正式调入港股通标的证券名单，该调整已于9月7日(周一)起生效。这意味着内地投资者自此可通过沪深港通直接买卖剂泰科技，正式解锁南向资金。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493156.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["07666","BK1191","AIPO","BK1161","BK1583","CHAT","VXUS","BK1606","BK4585","ARTY","BK4588","KCAI","VTHR","QTOC","02186","AGIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665467923","title":"港股异动 | 剂泰科技-P(07666.HK)早盘涨超7% 剂泰携手绿叶制药 成为其首家AI药物递送战略合作单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2665467923","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665467923?lang=zh_cn&edition=full","pubTime":"2026-09-08 10:03","pubTimestamp":1788832998,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","07666","02186","BK1161","BK1191","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134093467","title":"绿叶制药8月无新增发行及回购，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1134093467","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134093467?lang=zh_cn&edition=full","pubTime":"2026-09-04 16:53","pubTimestamp":1788512006,"startTime":"0","endTime":"0","summary":"绿叶制药集团有限公司于2026年9月4日公布2026年8月31日止股份变动月报。报告显示，公司当月未进行任何新增股份发行或回购活动，股本总体维持不变。根据公告数据，截至2026年8月31日，绿叶制药普通股的已发行股份数目为3,994,515,953股，与上月底相同。公司确认，目前符合香港联交所关于最低公众持股量的要求，并继续遵守相关上市规则及法律法规。公告由公司董事祝媛媛签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663021524","title":"港股异动 | 绿叶制药(02186)跌超9% 上半年增利不增收 肿瘤业务收入下滑超三成","url":"https://stock-news.laohu8.com/highlight/detail?id=2663021524","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663021524?lang=zh_cn&edition=full","pubTime":"2026-08-31 11:39","pubTimestamp":1788147547,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，绿叶制药跌超9%，截至发稿，跌9.62%，报1.925港元，成交额1.44亿港元。消息面上，绿叶制药发布2026年中期业绩，上半年公司收入为30.02亿元，同比减少5.6%；毛利减少至19.02亿元，毛利率为63.4%，同比下降11.8%；股东应占溢利为3.91亿元，增长24.8%。业务表现看，其传统的肿瘤业务承压明显，2026年上半年肿瘤治疗领域的收入为8.36亿元，同比下降35.5%。一年以内到期有息负债高达91.62亿元，短期偿债压力较重。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489267.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02186","VXUS","BK4585","KCAI","BK1583","BK1606","BK1191","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663104479","title":"肿瘤业务持续下行！绿叶制药上半年营收下滑净利增长，百亿有息负债压身","url":"https://stock-news.laohu8.com/highlight/detail?id=2663104479","media":"深圳商报·读创","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663104479?lang=zh_cn&edition=full","pubTime":"2026-08-30 22:42","pubTimestamp":1788100973,"startTime":"0","endTime":"0","summary":"8月30日，知名药企绿叶制药（02186）发布截至2026年6月30日止六个月的中期业绩公告。公告显示，上半年公司收入为30.02亿元，同比减少1.79亿元或5.6%；毛利减少至19.02亿元，毛利率为63.4%，同比下降11.8%；净利润为3.81亿元，同比增长6.5%；股东应占溢利为3.91亿元，增长24.8%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608303859511624.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608303859511624.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663340044","title":"绿叶制药上半年股东应占溢利3.91亿元 增长24.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663340044","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663340044?lang=zh_cn&edition=full","pubTime":"2026-08-30 20:13","pubTimestamp":1788091980,"startTime":"0","endTime":"0","summary":"8月30日，绿叶制药（02186）发布截至2026年6月30日止六个月的中期业绩公告。公告显示，公司收入为30.02亿元，较截至2025年6月30日止六个月减少1.79亿元或5.6%。毛利减少至19.02亿元，毛利率为63.4%，同比下降11.8%。净利润为3.81亿元，同比增长6.5%。股东应占溢利为3.91亿元，增长24.8%。EBITDA为12.51亿元，增长3.9%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608303859473727.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608303859473727.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02186","BK1606","BK1583","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162804592","title":"绿叶制药2026年中期营收30.02亿元，经调整净利润12.51亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1162804592","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162804592?lang=zh_cn&edition=full","pubTime":"2026-08-30 19:36","pubTimestamp":1788089810,"startTime":"0","endTime":"0","summary":"截至2026年6月30日，绿叶制药实现营收30.02亿元，同比下降5.6%。期内经调整净利润为12.51亿元，同比增长3.9%。报告期内毛利为19.02亿元，同比下降11.8%，毛利率为63.4%，相较上一年同期的67.8%降低4.4个百分点。研发投入约2.57亿元，同比提升32.8%。销售及分销费用约8.00亿元，同比减少21.5%，占收入的比例由去年的32.0%下降至26.7%；行政开支约3.25亿元，同比增长3.0%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"绿叶制药2026年中期营收30.02亿元，经调整净利润12.51亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663704177","title":"绿叶制药(02186.HK)发布中期业绩 股东应占溢利3.91亿元 同比增加24.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663704177","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663704177?lang=zh_cn&edition=full","pubTime":"2026-08-30 19:34","pubTimestamp":1788089651,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","BK1606","02186","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191333729","title":"绿叶制药：UBS Group AG减持，好仓比例降至12.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=1191333729","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191333729?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:32","pubTimestamp":1787909539,"startTime":"0","endTime":"0","summary":"2026年8月24日，UBS Group AG以每股均价2.1485港元卖出绿叶制药（02186）262.55万股，涉资约564.09万港元。UBS Group AG此次减持前持有绿叶制药好仓5.21亿，占比13.05%；减持后持股量为5.19亿，好仓比例降至12.98%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661256891","title":"港股异动 | 绿叶制药(02186.HK)早盘涨超6% mRNA疫苗LY01620即将开展中国II期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2661256891","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661256891?lang=zh_cn&edition=full","pubTime":"2026-08-21 09:33","pubTimestamp":1787275991,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","02186","BK1606","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660923801","title":"绿叶制药：mRNA疫苗LY01620将开展中国II期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2660923801","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660923801?lang=zh_cn&edition=full","pubTime":"2026-08-20 22:39","pubTimestamp":1787236740,"startTime":"0","endTime":"0","summary":"南财智讯8月20日电，绿叶制药（02186.HK）发布自愿公告，公告基本信息：公司于2026年8月20日发布自愿性公告，宣布自主研发的治疗性mRNA疫苗LY01620即将在中国开展II期临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608203848182093.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608203848182093.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BMED","MRNX","IBBQ","BK1191","02186","PSYK","BK1606","MDTX","IBBJ","BK1583","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104812966","title":"绿叶制药公布治疗性HPV mRNA疫苗LY01620即将在华启动II期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=1104812966","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104812966?lang=zh_cn&edition=full","pubTime":"2026-08-20 22:35","pubTimestamp":1787236532,"startTime":"0","endTime":"0","summary":"2026年8月20日，绿叶制药集团有限公司发布自愿性公告称，其自主研发的治疗性信使核糖核酸疫苗LY01620即将在中国开展II期临床试验。本次II期研究计划招募经组织学确诊的HPV16阳性子宫颈高级别鳞状上皮内病变患者，以进一步评估该产品的有效性和安全性。公司表示，LY01620有望填补HPV治疗性疫苗市场空白，并正积极探索其在其他HPV相关实体肿瘤中的临床应用。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134431558","title":"绿叶制药（02186）拟于8月29日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1134431558","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134431558?lang=zh_cn&edition=full","pubTime":"2026-08-17 22:05","pubTimestamp":1786975531,"startTime":"0","endTime":"0","summary":"绿叶制药集团有限公司（02186）8月17日发布公告称，公司董事会已订于2026年8月29日（星期六）召开会议，届时将审议截至2026年6月30日止六个月的中期业绩及其发布事宜，并考虑派发中期股息（如有）。\\n\\n根据公告，此次会议议程重点包括：1）批准公司及其附属公司2026年中期财务报告；2）就派发中期股息（如有）进行讨论与决定。\\n\\n公告同时列出了公司现任董事会成员，包括执行董事刘殿波、杨荣兵、袁会先、祝媛媛；非执行董事宋瑞霖、黄立明；以及独立非执行董事张化桥、卢毓琳、梁民杰、蔡思聪、夏莲。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116072707","title":"绿叶制药2026年7月股份变动月报：股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1116072707","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116072707?lang=zh_cn&edition=full","pubTime":"2026-08-06 16:38","pubTimestamp":1786005501,"startTime":"0","endTime":"0","summary":"绿叶制药集团有限公司于2026年8月6日发布2026年7月股份变动月报表。根据公告，截至2026年7月31日，公司法定注册股本总额维持在100亿股，普通股每股面值0.02美元，注册股本保持2亿美元，上月底与本月底相比未发生增减变化。公司在7月无新增发行、购回或注销股份，股本总量保持不变。在可换股票据方面，公司原有的于2028年到期、金额为1.8亿美元的6.25%可换股债券，期初余额为9,026万美元，已于2026年7月6日全部赎回并注销。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136715832","title":"绿叶制药创新药LY03015美国桥接试验完成　安全耐受性高加索组优于中国组","url":"https://stock-news.laohu8.com/highlight/detail?id=1136715832","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136715832?lang=zh_cn&edition=full","pubTime":"2026-08-05 21:06","pubTimestamp":1785935160,"startTime":"0","endTime":"0","summary":"绿叶制药集团有限公司（02186）8月5日公告，其自主研发的新分子实体LY03015已在美国成功完成桥接临床试验，为即将在美国开展的疗效临床试验提供支持。该试验发现，高加索人群较中国人群表现出更好的安全耐受性。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657547479","title":"绿叶制药：创新药LY03015在美完成桥接临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2657547479","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657547479?lang=zh_cn&edition=full","pubTime":"2026-08-05 21:05","pubTimestamp":1785935100,"startTime":"0","endTime":"0","summary":"南财智讯8月5日电，绿叶制药（02186.HK）发布自愿公告，公司自主研发的创新药LY03015（VMAT2抑制剂/Sigma-1R激动剂）在美国成功完成桥接临床试验，支持其即将开展的美国疗效临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608053832810135.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608053832810135.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","MDTX","159992","BK1574","BK1606","BK1161","BK1583","LNGR","PSYK","MEDX","IBBQ","02186","BMED","BK1191","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184468537","title":"异动解读｜绿叶制药盘中下跌5.41%，报2.09港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1184468537","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184468537?lang=zh_cn&edition=full","pubTime":"2026-07-17 10:41","pubTimestamp":1784256076,"startTime":"0","endTime":"0","summary":"7月17日，绿叶制药盘中下跌5.41%，报2.09港元/股，成交额5199.23万港元。绿叶制药所在的制药行业中，整体表现疲弱，个股中，石药集团跌5.93%，中国生物制药跌5.7%，翰森制药跌4.04%，恒瑞医药跌4.83%，凯莱英跌8.39%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100429752","title":"异动解读｜绿叶制药盘中上涨6.45%，可转债赎回叠加创新药临床利好持续推升","url":"https://stock-news.laohu8.com/highlight/detail?id=1100429752","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100429752?lang=zh_cn&edition=full","pubTime":"2026-07-15 09:49","pubTimestamp":1784080143,"startTime":"0","endTime":"0","summary":"7月15日，绿叶制药盘中上涨6.45%，报2.27港元，成交额7007.71万港元，连续三个交易日走强。此外，公司创新药LY03015治疗迟发性运动障碍的中国II期临床达到主要终点，最高剂量组应答率达76.5%，接近现有一线药物历史数据的两倍，公司计划推进中美III期临床。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182535620","title":"异动解读｜绿叶制药盘中上涨5.29%，可转债赎回叠加临床利好持续提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1182535620","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182535620?lang=zh_cn&edition=full","pubTime":"2026-07-14 10:15","pubTimestamp":1783995326,"startTime":"0","endTime":"0","summary":"7月14日，绿叶制药盘中上涨5.29%，报2.19港元，成交额9422.62万港元。消息面上，公司近期利好密集释放。7月6日，公司完成提前赎回全部未清偿的1.8亿美元6.25%利率2028年到期可转换债券，所有债券已赎回并注销，有效消除潜在股权稀释压力。同时，公司此前已完成发行1.8亿美元5.25%利率2031年到期新可转换债券，成功实现债务置换并将融资成本降低100个基点。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111370535","title":"异动解读｜绿叶制药盘中上涨5.73%，多重利好共振提振市场情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1111370535","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111370535?lang=zh_cn&edition=full","pubTime":"2026-07-13 10:10","pubTimestamp":1783908601,"startTime":"0","endTime":"0","summary":"7月13日，绿叶制药盘中上涨5.73%，报2.03港元，成交额5635.49万港元。消息面上，公司近期利好密集释放。7月6日，公司完成提前赎回全部未清偿的1.8亿美元6.25%利率2028年到期可转换债券，所有债券已赎回并注销，有效消除了潜在的股权稀释压力。此外，公司已于6月完成发行1.8亿美元5.25%利率2031年到期新可转换债券，成功实现债务置换并降低融资成本。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02186"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.luye.cn","stockEarnings":[{"period":"1week","weight":-0.0501},{"period":"1month","weight":-0.1449},{"period":"3month","weight":-0.0476},{"period":"6month","weight":-0.2593},{"period":"1year","weight":-0.4986},{"period":"ytd","weight":-0.3431}],"compareEarnings":[{"period":"1week","weight":-0.033},{"period":"1month","weight":-0.0249},{"period":"3month","weight":0.0035},{"period":"6month","weight":-0.0259},{"period":"1year","weight":-0.0491},{"period":"ytd","weight":-0.0322}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"绿叶制药集团有限公司是一家主要从事药品的开发、生产、推广及销售的公司。该公司经营四个分部，包括肿瘤药物分部、心血管系统药物分部、消化与代谢药物分部和中枢神经系统药物分部。肿瘤药物分部提供力扑素、博优诺、百拓维、希美纳及米美欣等药品。心血管系统药物分部提供血脂康、欧开及麦通纳等药品。消化与代谢药物分部提供贝希等药品。中枢神经系统药物分部提供思瑞康、若欣林、瑞可妥、美比瑞及金悠平等药品。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.024212},{"month":2,"riseRate":0.333333,"avgChangeRate":0.016158},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.022436},{"month":4,"riseRate":0.5,"avgChangeRate":-0.006455},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.020854},{"month":6,"riseRate":0.333333,"avgChangeRate":0.018146},{"month":7,"riseRate":0.666667,"avgChangeRate":0.027172},{"month":8,"riseRate":0.153846,"avgChangeRate":-0.044807},{"month":9,"riseRate":0.538462,"avgChangeRate":0.036871},{"month":10,"riseRate":0.5,"avgChangeRate":-0.00637},{"month":11,"riseRate":0.5,"avgChangeRate":0.024651},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.012685}],"exchange":"SEHK","name":"绿叶制药","nameEN":"LUYE PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"绿叶制药(02186)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供绿叶制药(02186)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"绿叶制药,02186,绿叶制药股票,绿叶制药股票老虎,绿叶制药股票老虎国际,绿叶制药行情,绿叶制药股票行情,绿叶制药股价,绿叶制药股市,绿叶制药股票价格,绿叶制药股票交易,绿叶制药股票购买,绿叶制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"绿叶制药(02186)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供绿叶制药(02186)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}